Banner Image

Test Directory

FISH, ALK 2p23 Rearrangement, Lung Cancer (NSCLC)

Order Code: LC2P23

Test Summary

Non-small cell lung cancer is the leading cause of cancer death worldwide. Tyrosine kinase inhibitors have been demonstrated to reduce lung cancer cell proliferation. The therapeutic efficacy of inhibiting ALK in tumors that were selected by ALK positivity using FISH has been demonstrated in an early-phase clinical trial of a small molecular inhibitor of the ALK tyrosine kinase. The Vysis ALK Break Apart FISH probe kit is a qualitative test to detect rearrangements involving the ALK gene in formalin-fixed paraffin embedded non-small cell lung cancer tissue specimens to aid in identifying those patients eligible for treatment with XALKOR (crizotinib).

Aliases

  • N/A

Specimen Collection

Order Code

LC2P23

EPIC (Premier) Code

LAB5206

Includes

N/A

CPT Code

  • 88271 (x2)
  • 88274

Billing Code

  • 671064
  • 671065

CPT Statement

Methodology

Fluorescence In Situ Hybridization (FISH)

FDA Status

The analytical performance characteristics of this assay have been determined by Quest Diagnostics Nichols Institute. The modifications have not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Physician Attestation of Informed Consent

N/A

Testing Laboratory

Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly VA, 20153

Department

Reference Testing

Reference Range

See Laboratory Report

Setup Schedule / Expected Turnaround Time

Daily; Report available: 7 days

Specimen Collection

Billing

CPT Code

  • 88271 (x2)
  • 88274

Billing Code

  • 671064
  • 671065

CPT Statement

Result Information

Methodology

Fluorescence In Situ Hybridization (FISH)

Testing Laboratory

N/A

Reference Range

See Laboratory Report

Setup Schedule / Expected Turnaround Time

Daily; Report available: 7 days